A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for triple-negative breast cancer (fRida)
31/01/2016
Autori: JC Chang, AF Schott, MS Wicha, M Cristofanilli, PA Ruffini, S McCanna, LJ Goldstein
Pubblicato in:
Cancer Research